Citi lowered the firm’s price target on Bio-Techne (TECH) to $70 from $80 and keeps a Buy rating on the shares. The firm reduced the company’s estimates post the fiscal Q3 report. Bio-Techne guided Q4 to flat organic growth, below expectations of up 4%, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH: